Josh Allen

CTO, Imipridones

Joshua Allen, PhD, joined Chimerix in 2021 as Chief Technology Officer, Imipridones in 2021. Dr. Allen discovered the anti-cancer activity of ONC201 and co-invented the imipridone class of compounds. Dr. Allen has continuously advanced the research and development of ONC201 from academic discovery to its registration program, along with the crea...

Roles at Chimerix

  • CTO, Imipridones

    Current role

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.